- Home
- OMH vs CYCN Comparison
OMH vs CYCN Comparison
Compare OMH & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMH
- CYCN
- Stock Information
- Founded
- OMH 2015
- CYCN 2018
- Country
- OMH Singapore
- CYCN United States
- Employees
- OMH N/A
- CYCN N/A
- Industry
- OMH Real Estate
- CYCN Biotechnology: Pharmaceutical Preparations
- Sector
- OMH Finance
- CYCN Health Care
- Exchange
- OMH Nasdaq
- CYCN Nasdaq
- Market Cap
- OMH 13.6M
- CYCN 6.5M
- IPO Year
- OMH 2023
- CYCN N/A
- Fundamental
- Price
- OMH $1.45
- CYCN $2.80
- Analyst Decision
- OMH Hold
- CYCN
- Analyst Count
- OMH 1
- CYCN 0
- Target Price
- OMH N/A
- CYCN N/A
- AVG Volume (30 Days)
- OMH 5.5M
- CYCN 21.8K
- Earning Date
- OMH 07-11-2025
- CYCN 08-06-2025
- Dividend Yield
- OMH N/A
- CYCN N/A
- EPS Growth
- OMH N/A
- CYCN N/A
- EPS
- OMH N/A
- CYCN N/A
- Revenue
- OMH $7,976,578.00
- CYCN $2,081,000.00
- Revenue This Year
- OMH $28.40
- CYCN N/A
- Revenue Next Year
- OMH $23.07
- CYCN N/A
- P/E Ratio
- OMH N/A
- CYCN N/A
- Revenue Growth
- OMH 117.53
- CYCN N/A
- 52 Week Low
- OMH $0.59
- CYCN $1.27
- 52 Week High
- OMH $6.20
- CYCN $9.47
- Technical
- Relative Strength Index (RSI)
- OMH 46.11
- CYCN 41.24
- Support Level
- OMH $1.45
- CYCN $3.02
- Resistance Level
- OMH $1.59
- CYCN $3.16
- Average True Range (ATR)
- OMH 0.40
- CYCN 0.21
- MACD
- OMH 0.02
- CYCN -0.03
- Stochastic Oscillator
- OMH 35.76
- CYCN 16.26
About OMH Ohmyhome Limited
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.